HK Stock Market Move | Taiwan (09890) surged over 8% in the morning session with the company issuing HK$468 million in zero-interest convertible bonds to build core competitive strength in AI+ games.
Greed (09890) surged more than 8% in early trading, as of the time of writing, it was up 6.91% to HK$17.01, with a turnover of HK$32.4998 million.
TANWAN (09890) rose more than 8% in the early trading session, rising 6.91% as of the time of writing, to HK$17.01, with a trading volume of HK$3249.98 million.
On the news front, TANWAN recently announced its plan to issue HK$468 million zero-coupon convertible bonds, with an initial conversion price of HK$23.50 per share, representing a premium of approximately 38.24% over the closing price of HK$17.00 per share on the last trading day before the agreement date on the Hong Kong Stock Exchange. The net proceeds from the issuance of the convertible bonds, approximately HK$4.586 billion, will be used for investments in AI-related businesses and equity investments in the AI industry to accelerate the company's strategic layout in the "AI + gaming" sector.
It is reported that the convertible bonds are fully subscribed by the internationally renowned investment management fund LMR Partners. LMR Partners is headquartered in London and has offices in New York, Hong Kong, Zurich, Dubai, Dublin, and Glasgow. This cooperation with LMR introduces long-term, stable, high-quality international funds to the company, helping to optimize the capital structure, and enhance the company's visibility and influence in the global capital market.
Related Articles

YOFC(06869): Shareholder Wuhan Yangtze Communication Industry Group has accumulated a reduction of 1.1 million A shares.

ZGC TEC LEASING (01601) Signs Financing Lease Agreement

FUSEN PHARM(01652): "Compound Potassium Dihydrogen Phosphate Injection" approved for market.
YOFC(06869): Shareholder Wuhan Yangtze Communication Industry Group has accumulated a reduction of 1.1 million A shares.

ZGC TEC LEASING (01601) Signs Financing Lease Agreement

FUSEN PHARM(01652): "Compound Potassium Dihydrogen Phosphate Injection" approved for market.

RECOMMEND

Not Just “Power Shortages,” Delays Will Become The Key Theme For U.S. Data Centers In 2026
26/12/2025

Hang Seng Index Rises 33% This Year, Best Five‑Year Performance; Multiple Institutions Forecast Breakthrough Above 30,000 Next Year
26/12/2025

Gold Rally Has Further To Run, JPMorgan Bullish: Prices Could Reach USD 5,055 By Year‑End 2026
26/12/2025


